- Previous Close
6.77 - Open
6.78 - Bid --
- Ask --
- Day's Range
6.78 - 6.79 - 52 Week Range
6.50 - 23.50 - Volume
1,042 - Avg. Volume
38,771 - Market Cap (intraday)
8.966M - Beta (5Y Monthly) 1.25
- PE Ratio (TTM)
-- - EPS (TTM)
-19.11 - Earnings Date Nov 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.00
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
galecto.comRecent News: GLTO
View More
Performance Overview: GLTO
Trailing total returns as of 11/14/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLTO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLTO
View MoreValuation Measures
Market Cap
9.07M
Enterprise Value
-10.57M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.43
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.29%
Return on Equity (ttm)
-72.61%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-21.17M
Diluted EPS (ttm)
-19.11
Balance Sheet and Cash Flow
Total Cash (mrq)
19.68M
Total Debt/Equity (mrq)
0.15%
Levered Free Cash Flow (ttm)
-16.52M
Research Analysis: GLTO
View MoreCompany Insights: GLTO
GLTO does not have Company Insights